A recent phase 2 randomized controlled trial reported that short-term treatment with ISIS 304801, a second-generation antisense inhibitor of apolipoprotein C-III (APOC3) synthesis, reduced triglyceride levels in patients with severe or uncontrolled hypertriglyceridemia. High triglyceride levels can cause insulin resistance, metabolic syndrome, diabetes, cardiovascular disease. Reducing APOC3, a key regulator of plasma triglyceride levels, may be cardioprotective and lower the risk of pancreatitis in patients with very high triglyceride levels, according to the investigators (Gaudet D et al. N Engl J Med. 2015;373:438-447).
Slomski A. Antisense Inhibitor Lowers High Triglycerides. JAMA. 2015;314(12):1217. doi:10.1001/jama.2015.11081
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: